HK1225656A1 - 結合人類補體c5的穩定多肽 - Google Patents

結合人類補體c5的穩定多肽

Info

Publication number
HK1225656A1
HK1225656A1 HK16114209A HK16114209A HK1225656A1 HK 1225656 A1 HK1225656 A1 HK 1225656A1 HK 16114209 A HK16114209 A HK 16114209A HK 16114209 A HK16114209 A HK 16114209A HK 1225656 A1 HK1225656 A1 HK 1225656A1
Authority
HK
Hong Kong
Prior art keywords
human complement
polypeptides binding
stable polypeptides
stable
binding
Prior art date
Application number
HK16114209A
Other languages
English (en)
Inventor
Joakim Nilsson
Erik Nordling
Patrik Strömberg
Original Assignee
Swedish Orphan Biovitrum Ab Publ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Swedish Orphan Biovitrum Ab Publ filed Critical Swedish Orphan Biovitrum Ab Publ
Publication of HK1225656A1 publication Critical patent/HK1225656A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
HK16114209A 2013-08-28 2016-12-14 結合人類補體c5的穩定多肽 HK1225656A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE1350986 2013-08-28

Publications (1)

Publication Number Publication Date
HK1225656A1 true HK1225656A1 (zh) 2017-09-15

Family

ID=51539238

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16114209A HK1225656A1 (zh) 2013-08-28 2016-12-14 結合人類補體c5的穩定多肽

Country Status (29)

Country Link
US (1) US9994626B2 (zh)
EP (2) EP3811961A1 (zh)
JP (2) JP6767865B2 (zh)
KR (1) KR102446636B1 (zh)
CN (1) CN105658228B (zh)
AU (1) AU2014314222B2 (zh)
BR (2) BR112016003142A2 (zh)
CA (1) CA2926976C (zh)
CY (1) CY1123732T1 (zh)
DK (1) DK3038633T3 (zh)
ES (1) ES2842105T3 (zh)
HK (1) HK1225656A1 (zh)
HR (1) HRP20210013T1 (zh)
HU (1) HUE052613T2 (zh)
IL (1) IL244218A (zh)
LT (1) LT3038633T (zh)
MX (1) MX2016002397A (zh)
MY (1) MY173804A (zh)
NZ (1) NZ718153A (zh)
PH (1) PH12016500371B1 (zh)
PL (1) PL3038633T3 (zh)
PT (1) PT3038633T (zh)
RS (1) RS61347B1 (zh)
RU (2) RU2733897C2 (zh)
SA (1) SA516370622B1 (zh)
SG (1) SG11201602679VA (zh)
SI (1) SI3038633T1 (zh)
UA (1) UA117933C2 (zh)
WO (1) WO2015028558A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2817329T3 (en) * 2012-02-20 2019-04-01 Swedish Orphan Biovitrum Ab Publ Polypeptides Binding to Human Complement Component C5.
CN116987154A (zh) * 2013-08-28 2023-11-03 阿菲博迪公司 具有突变的支架的结合多肽
PT3038633T (pt) * 2013-08-28 2021-01-14 Ipc Res Llc Polipéptidos estáveis que se ligam ao complemento humano c5
UY37651A (es) * 2017-03-31 2018-10-31 Swedish Orphan Biovitrum Ab Publ Polipéptido de unión al il-1r-i
JP2020532285A (ja) 2017-07-11 2020-11-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体成分ｃ５または血清アルブミンと結合するポリペプチドおよびその融合タンパク質
AU2022377077A1 (en) * 2021-11-01 2024-05-16 Ipc Research, Llc Administration of c5-binding proteins

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
WO2002030985A2 (en) 2000-10-10 2002-04-18 Tanox, Inc. Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
US7432356B2 (en) 2001-08-17 2008-10-07 Genentech, Inc. Complement pathway inhibitors binding to C5 and C5a without preventing formation of C5b
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
CA2579635A1 (en) * 2003-09-10 2005-03-17 Baxter International Inc. Peptides that inhibit complement activation
SE0400274D0 (sv) * 2004-02-09 2004-02-09 Affibody Ab New polypeptide
GB0518443D0 (en) 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
MX2008011323A (es) * 2006-03-08 2008-11-18 Archemix Corp Aptameros que se unen al complemento y agentes anti-c5 utiles en el tratamiento de trastornos oculares.
SI2359834T1 (sl) 2006-03-15 2017-02-28 Alexion Pharmaceuticals, Inc. Zdravljenje pacientov,ki imajo paroksizmalno nočno hemoglobinurijo, z zaviralcem komplementa
DK2190863T3 (en) 2007-07-31 2015-11-30 Affibody Ab New albumin binding compositions, methods and uses
US9187535B2 (en) 2007-12-19 2015-11-17 Affibody Ab Polypeptide derived from protein A and able to bind PDGF
DK2231860T3 (da) 2007-12-19 2011-12-05 Affibody Ab Polypeptid afledt protein A og i stand til at binde PDGF
EP2072525A1 (en) 2007-12-21 2009-06-24 Affibody AB New polypeptides having affinity for HER2
JP5815403B2 (ja) 2008-08-05 2015-11-17 ノバルティス アーゲー 補体タンパク質ｃ５を標的とする抗体に関する組成物および方法
EP2327725A1 (en) 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
EP2933262B1 (en) 2010-07-09 2018-05-02 Affibody AB Polypeptides
DK2817329T3 (en) * 2012-02-20 2019-04-01 Swedish Orphan Biovitrum Ab Publ Polypeptides Binding to Human Complement Component C5.
JP5980104B2 (ja) 2012-11-22 2016-08-31 三菱電機株式会社 液晶表示装置の製造方法および液晶表示装置の製造システム
JP6577868B2 (ja) 2012-12-19 2019-09-18 アフィボディ・アーベー 新規ポリペプチド
PT3038633T (pt) * 2013-08-28 2021-01-14 Ipc Res Llc Polipéptidos estáveis que se ligam ao complemento humano c5
CN116987154A (zh) * 2013-08-28 2023-11-03 阿菲博迪公司 具有突变的支架的结合多肽

Also Published As

Publication number Publication date
MX2016002397A (es) 2016-09-08
EP3811961A1 (en) 2021-04-28
CA2926976A1 (en) 2015-03-05
EP3038633B1 (en) 2020-10-14
KR20160048121A (ko) 2016-05-03
JP6767865B2 (ja) 2020-10-14
SI3038633T1 (sl) 2021-05-31
CA2926976C (en) 2023-11-28
JP2020172505A (ja) 2020-10-22
CN105658228B (zh) 2020-02-07
EP3038633A1 (en) 2016-07-06
IL244218A (en) 2017-11-30
RU2016111115A3 (zh) 2018-04-25
PH12016500371A1 (en) 2016-05-02
RU2020128977A (ru) 2021-11-30
DK3038633T3 (da) 2021-01-11
RS61347B1 (sr) 2021-02-26
WO2015028558A1 (en) 2015-03-05
AU2014314222B2 (en) 2018-05-24
BR112016003142A2 (pt) 2017-10-17
BR122023020080A2 (pt) 2023-12-26
LT3038633T (lt) 2021-03-25
RU2733897C2 (ru) 2020-10-09
ES2842105T3 (es) 2021-07-12
UA117933C2 (uk) 2018-10-25
MY173804A (en) 2020-02-24
US20160311870A1 (en) 2016-10-27
PT3038633T (pt) 2021-01-14
PL3038633T3 (pl) 2021-07-19
IL244218A0 (en) 2016-04-21
AU2014314222A1 (en) 2016-04-21
CN105658228A (zh) 2016-06-08
HRP20210013T1 (hr) 2021-04-02
CY1123732T1 (el) 2021-10-29
SG11201602679VA (en) 2016-05-30
PH12016500371B1 (en) 2016-05-02
NZ718153A (en) 2022-05-27
JP2016529270A (ja) 2016-09-23
HUE052613T2 (hu) 2021-05-28
US9994626B2 (en) 2018-06-12
KR102446636B1 (ko) 2022-09-23
SA516370622B1 (ar) 2018-12-23
RU2016111115A (ru) 2017-10-03

Similar Documents

Publication Publication Date Title
IL267724B (en) Human c5 complement-binding polypeptides
IL275376A (en) Polypeptides with hyperglycosidic bonds
IL240838A0 (en) Anti-3–lag binding proteins
HK1225656A1 (zh) 結合人類補體c5的穩定多肽
HK1218920A1 (zh) 改善的 結合蛋白
ZA201507808B (en) Binding element
ZA201600535B (en) Cosmetic composition
SG11201508627XA (en) Peptides binding to parallel-stranded g-quadruplexes
GB201303977D0 (en) Binding polypeptides
GB201318147D0 (en) Herbal composition
GB201318146D0 (en) Herbal composition
GB201310949D0 (en) Binding Motif